BioArctic (BATS-CHIXE:BIOABS) - Cotización, noticias y análisis

Resumen de acción BIOABS

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden.

BIOABS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 64.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 46.73%

Los beneficios aumentaron un 832.1% el pasado año

Análisis de riesgos

Acciones altamente ilíquidas

Competidores de BioArctic AB (publ)

Genus

LSE:GNS

UK£1.2b

Bioventix

AIM:BVXP

UK£228.4m

HUTCHMED (China)

AIM:HCM

UK£3.0b

TG Therapeutics

NasdaqCM:TGTX

US$2.4b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for BioArctic
Historical stock prices
Current Share Price	kr279.80
52 Week High	kr352.60
52 Week Low	kr231.60
Beta	-0.16
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-0.14%
3 Year Change	201.35%
5 Year Change	245.43%
Change since IPO	850.08%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	BIOABS	GB Biotechs	Mercado GB
7D	0%	0.9%	2.5%
1Y	-0.1%	-22.0%	5.8%

Rentabilidad vs. Industria: BIOABS superó al sector UK Biotechs , que obtuvo un rendimiento del -30.5% el año pasado.

Rentabilidad vs. Mercado: BIOABS igualó al mercado UK, que obtuvo un rendimiento del -1.8% el año pasado.

Volatilidad de los precios

Is BIOABS's price volatile compared to industry and market?
BIOABS volatility
BIOABS Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.8%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: BIOABS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de BIOABS en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2000	83	Gunilla Osswald	www.bioarctic.se

Resumen de fundamentos de BioArctic AB (publ)

¿Cómo se comparan los beneficios e ingresos de BioArctic con su capitalización de mercado?
Estadísticas fundamentales de BIOABS
Capitalización bursátil	kr23.84b
Beneficios(TTM)	kr258.61m
Ingresos (TTM)	kr610.52m

92.2x

Ratio precio-beneficio (PE)

39.1x

Ratio precio-ventas (PS)

¿Está BIOABS sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BIOABS
Ingresos	kr610.52m
Coste de los ingresos	kr75.27m
Beneficio bruto	kr535.25m
Otros gastos	kr276.64m
Beneficios	kr258.61m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

Feb 14, 2024

Beneficios por acción (BPA)	2.93
Margen bruto	87.67%
Margen de beneficio neto	42.36%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado BIOABS a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BIOABS

Recompensas

Análisis de riesgos

Competidores de BioArctic AB (publ)

LSE:GNS

UK£1.2b

AIM:BVXP

UK£228.4m

AIM:HCM

UK£3.0b

NasdaqCM:TGTX

US$2.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Second quarter 2023 earnings released: kr1.16 loss per share (vs kr0.52 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Recent updates

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Second quarter 2023 earnings released: kr1.16 loss per share (vs kr0.52 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Independent Director recently sold kr3.3m worth of stock

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Insufficient new directors

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

Insufficient new directors

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease

Third quarter 2022 earnings released

Insufficient new directors

BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

BioArctic AB (publ), Annual General Meeting, Jun 01, 2023

Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects

Insufficient new directors

Bioarctic AB (Publ) Announces Latest Data on Lecanemab Presented At Alzheimer's Association International Conference (Aaic)

Full year 2021 earnings released: kr1.36 loss per share (vs kr0.78 loss in FY 2020)

Bioarctic AB Announces Executive Changes

BioArctic AB (publ) to Report Fiscal Year 2021 Final Results on Mar 31, 2022

DIAN-TU Enrolls First Subject for the Tau Nexgen Study with Lecanemab as Back-Ground Anti-Amyloid Treatment

Bioarctic AB (Publ) Announces Lecanemab Granted Fast Track Designation by the FDA

Insufficient new directors

BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease

Independent Director has left the company

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de BioArctic AB (publ)

92.2x

39.1x

Beneficios e Ingresos